A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Aveo will soon find out whether Fotivda has a future, while Glaxo awaits data with an even longer-lasting HIV doublet.
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
Newly-listed NGM Biopharmaceuticals needs its Nash project to impress in phase II, while Enanta must show that it also has a foot in the door in the liver disease.
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.